Equities research analysts expect that Aethlon Medical, Inc. (NASDAQ:AEMD) will announce earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aethlon Medical’s earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.07). Aethlon Medical posted earnings per share of ($0.08) in the same quarter last year, which indicates a positive year over year growth rate of 12.5%. The business is scheduled to issue its next earnings results on Thursday, February 7th.
On average, analysts expect that Aethlon Medical will report full-year earnings of ($0.27) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.26). For the next financial year, analysts forecast that the company will report earnings of ($0.30) per share, with EPS estimates ranging from ($0.35) to ($0.25). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Aethlon Medical.
Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings results on Tuesday, November 6th. The medical equipment provider reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.01).
Separately, HC Wainwright set a $3.00 price target on Aethlon Medical and gave the stock a “buy” rating in a report on Thursday, August 9th.
A hedge fund recently bought a new stake in Aethlon Medical stock. Millennium Management LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 200,210 shares of the medical equipment provider’s stock, valued at approximately $238,000. Millennium Management LLC owned 1.20% of Aethlon Medical at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.42% of the company’s stock.
Aethlon Medical stock opened at $1.17 on Friday. Aethlon Medical has a one year low of $0.82 and a one year high of $2.04. The firm has a market capitalization of $20.89 million, a PE ratio of -2.54 and a beta of 2.11.
About Aethlon Medical
Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals.
Featured Article: Discount Rate
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.